Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOUNG-HOPE: Response-guided therapy after neoadjuvant endocrine therapy in premenopausal HR+HER2- breast cancer
jRCTs031250687Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of tamoxifen in breast cancer (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Event-free survival. Started Feb 2026; status: recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs031250687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250687.